Clinical Trial Update: A Bioequivalence Study of Two Different Dosage Form of Genakumab [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1 bioequivalence study comparing two dosage forms of Genakumab for gouty arthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gouty Arthritis

Drugs mentioned

• Genakumab

Snippet

Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. | Conditions: Gouty Arthritis (GA) | Phase 1 | Status: COMPLETED